Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast

被引:30
作者
Jamiyan, Tsengelmaa [1 ,5 ]
Kuroda, Hajime [1 ]
Yamaguchi, Rin [2 ]
Nakazato, Yoshimasa [1 ]
Noda, Shuhei [1 ]
Onozaki, Masato [1 ]
Abe, Akihito [3 ,4 ]
Hayashi, Mitsuhiro [3 ]
机构
[1] Dokkyo Med Univ, Dept Diagnost Pathol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan
[2] Kurume Univ, Dept Pathol & Lab Med, Med Ctr, Kurume, Fukuoka, Japan
[3] Dokkyo Med Univ, Breast Ctr, Dokkyo, Japan
[4] Dokkyo Med Univ, Dept Surg 2, Dokkyo, Japan
[5] Mongolian Natl Univ Med Sci, Dept Pathol & Forens Med, Ulan Bator, Mongolia
关键词
Breast; Triple negative cancer; CD4; CD8; FOXP3; REGULATORY T-CELLS; CARCINOMA; EXPRESSION; CD4(+); SURVIVAL;
D O I
10.1007/s12282-020-01084-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Tumor-infiltrating lymphocytes (TILs) have recently been reported as an important factor in the tumor microenvironment and influence the growth and progression of cancer. However, the relationship between immune cell subpopulations, such as CD4+, CD8+, and FOXP3+, in breast cancer, especially in triple negative carcinoma (TNC), remains unclear. Methods The subjects were 107 patients with TNC that were surgically resected at Dokkyo Medical University Hospital between 2006 and 2018. The expression of CD4+, CD8+, and FOXP3+ was evaluated in TILs and expressed as the numbers of positive cells. Results Univariate analysis revealed that the TILs were not prognostically significant. In multivariate analyses, increased infiltration of intratumoral (i) CD4+ TILs was found to have a good prognosis in relapse-free survival (RFS). In contrast, a high stromal CD8+ TILs level was found to be a favorable prognostic factor in RFS (p = 0.038) and overall survival (OS) (p = 0.046). A low sFOXP3 + TILs level was significantly associated with favorable RFS (p < 0.001) and OS (p = 0.029). Conclusions The present study demonstrated no difference in TILs and survival in TNC. However, there was a significant correlation in prognosis with levels of iCD4+, sCD8+, and sFOXP3 + TILs in TNC. The difference in TNC clinical outcome may be due to the subtype of the infiltrating TILs.
引用
收藏
页码:880 / 892
页数:13
相关论文
共 39 条
[1]   LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].
AALTOMAA, S ;
LIPPONEN, P ;
ESKELINEN, M ;
KOSMA, VM ;
MARIN, S ;
ALHAVA, E ;
SYRJANEN, K .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864
[2]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[3]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[4]  
Ashida A, 2006, INT J ONCOL, V28, P1345
[5]   Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].
Bates, Gaynor J. ;
Fox, Stephen B. ;
Han, Cheng ;
Leek, Russell D. ;
Garcia, Jose F. ;
Harris, Adrian L. ;
Banham, Alison H. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380
[6]   Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target [J].
Bohling, Sandra D. ;
Allison, Kimberly H. .
MODERN PATHOLOGY, 2008, 21 (12) :1527-1532
[7]   Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy [J].
Castaneda, Carlos A. ;
Mittendorf, Elizabeth ;
Casavilca, Sandro ;
Wu, Yun ;
Castillo, Miluska ;
Arboleda, Patricia ;
Nunez, Teresa ;
Guerra, Henry ;
Barrionuevo, Carlos ;
Dolores-Cerna, Ketty ;
Belmar-Lopez, Carolina ;
Abugattas, Julio ;
Calderon, Gabriela ;
De La Cruz, Miguel ;
Cotrina, Manuel ;
Dunstan, Jorge ;
Gomez, Henry L. ;
Vidaurre, Tatiana .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (05) :387-394
[8]   Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression [J].
DeNardo, David G. ;
Coussens, Lisa M. .
BREAST CANCER RESEARCH, 2007, 9 (04)
[9]   Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Darb-Esfahani, Silvia ;
Lederer, Bianca ;
Heppner, Barbara I. ;
Weber, Karsten E. ;
Budczies, Jan ;
Huober, Jens ;
Klauschen, Frederick ;
Furlanetto, Jenny ;
Schmitt, Wolfgang D. ;
Blohmer, Jens-Uwe ;
Karn, Thomas ;
Pfitzner, Berit M. ;
Kuemmel, Sherko ;
Engels, Knut ;
Schneeweiss, Andreas ;
Hartmann, Arndt ;
Noske, Aurelia ;
Fasching, Peter A. ;
Jackisch, Christian ;
van Mackelenbergh, Marion ;
Sinn, Peter ;
Schem, Christian ;
Hanusch, Claus ;
Untch, Michael ;
Loibl, Sibylle .
LANCET ONCOLOGY, 2018, 19 (01) :40-50
[10]   CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma [J].
Fukunaga, A ;
Miyamoto, M ;
Cho, Y ;
Murakami, S ;
Kawarada, Y ;
Oshikiri, T ;
Kato, K ;
Kurokawa, T ;
Suzuoki, M ;
Nakakubo, Y ;
Hiraoka, K ;
Itoh, T ;
Morikawa, T ;
Okushiba, S ;
Kondo, S ;
Katoh, H .
PANCREAS, 2004, 28 (01) :E26-E31